These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

792 related articles for article (PubMed ID: 30029672)

  • 1. Epigenomic profiling of non-small cell lung cancer xenografts uncover LRP12 DNA methylation as predictive biomarker for carboplatin resistance.
    Grasse S; Lienhard M; Frese S; Kerick M; Steinbach A; Grimm C; Hussong M; Rolff J; Becker M; Dreher F; Schirmer U; Boerno S; Ramisch A; Leschber G; Timmermann B; Grohé C; Lüders H; Vingron M; Fichtner I; Klein S; Odenthal M; Büttner R; Lehrach H; Sültmann H; Herwig R; Schweiger MR
    Genome Med; 2018 Jul; 10(1):55. PubMed ID: 30029672
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Epigenetic inactivation of the putative DNA/RNA helicase SLFN11 in human cancer confers resistance to platinum drugs.
    Nogales V; Reinhold WC; Varma S; Martinez-Cardus A; Moutinho C; Moran S; Heyn H; Sebio A; Barnadas A; Pommier Y; Esteller M
    Oncotarget; 2016 Jan; 7(3):3084-97. PubMed ID: 26625211
    [TBL] [Abstract][Full Text] [Related]  

  • 3. An apoptosis methylation prognostic signature for early lung cancer in the IFCT-0002 trial.
    de Fraipont F; Levallet G; Creveuil C; Bergot E; Beau-Faller M; Mounawar M; Richard N; Antoine M; Rouquette I; Favrot MC; Debieuvre D; Braun D; Westeel V; Quoix E; Brambilla E; Hainaut P; Moro-Sibilot D; Morin F; Milleron B; Zalcman G;
    Clin Cancer Res; 2012 May; 18(10):2976-86. PubMed ID: 22434665
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Genome-wide methylation profiling of ovarian cancer patient-derived xenografts treated with the demethylating agent decitabine identifies novel epigenetically regulated genes and pathways.
    Tomar T; de Jong S; Alkema NG; Hoekman RL; Meersma GJ; Klip HG; van der Zee AG; Wisman GB
    Genome Med; 2016 Oct; 8(1):107. PubMed ID: 27765068
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Low expression of ITIH5 in adenocarcinoma of the lung is associated with unfavorable patients' outcome.
    Dötsch MM; Kloten V; Schlensog M; Heide T; Braunschweig T; Veeck J; Petersen I; Knüchel R; Dahl E
    Epigenetics; 2015; 10(10):903-12. PubMed ID: 26252352
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Excision repair cross-complementation group 1 (ERCC1) in platinum-based treatment of non-small cell lung cancer with special emphasis on carboplatin: a review of current literature.
    Vilmar A; Sørensen JB
    Lung Cancer; 2009 May; 64(2):131-9. PubMed ID: 18804893
    [TBL] [Abstract][Full Text] [Related]  

  • 7. An integrated epigenomic-transcriptomic landscape of lung cancer reveals novel methylation driver genes of diagnostic and therapeutic relevance.
    Sun X; Yi J; Yang J; Han Y; Qian X; Liu Y; Li J; Lu B; Zhang J; Pan X; Liu Y; Liang M; Chen E; Liu P; Lu Y
    Theranostics; 2021; 11(11):5346-5364. PubMed ID: 33859751
    [No Abstract]   [Full Text] [Related]  

  • 8. Taxane-Platin-Resistant Lung Cancers Co-develop Hypersensitivity to JumonjiC Demethylase Inhibitors.
    Dalvi MP; Wang L; Zhong R; Kollipara RK; Park H; Bayo J; Yenerall P; Zhou Y; Timmons BC; Rodriguez-Canales J; Behrens C; Mino B; Villalobos P; Parra ER; Suraokar M; Pataer A; Swisher SG; Kalhor N; Bhanu NV; Garcia BA; Heymach JV; Coombes K; Xie Y; Girard L; Gazdar AF; Kittler R; Wistuba II; Minna JD; Martinez ED
    Cell Rep; 2017 May; 19(8):1669-1684. PubMed ID: 28538184
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Genomewide DNA methylation analysis identifies novel methylated genes in non-small-cell lung carcinomas.
    Carvalho RH; Hou J; Haberle V; Aerts J; Grosveld F; Lenhard B; Philipsen S
    J Thorac Oncol; 2013 May; 8(5):562-73. PubMed ID: 23524404
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Methylation of multiple genes as a candidate biomarker in non-small cell lung cancer.
    Zhang Y; Wang R; Song H; Huang G; Yi J; Zheng Y; Wang J; Chen L
    Cancer Lett; 2011 Apr; 303(1):21-8. PubMed ID: 21255913
    [TBL] [Abstract][Full Text] [Related]  

  • 11. IGFBP-3 hypermethylation-derived deficiency mediates cisplatin resistance in non-small-cell lung cancer.
    Ibanez de Caceres I; Cortes-Sempere M; Moratilla C; Machado-Pinilla R; Rodriguez-Fanjul V; Manguán-García C; Cejas P; López-Ríos F; Paz-Ares L; de CastroCarpeño J; Nistal M; Belda-Iniesta C; Perona R
    Oncogene; 2010 Mar; 29(11):1681-90. PubMed ID: 20023704
    [TBL] [Abstract][Full Text] [Related]  

  • 12. DNA methylation profiling defines clinically relevant biological subsets of non-small cell lung cancer.
    Walter K; Holcomb T; Januario T; Du P; Evangelista M; Kartha N; Iniguez L; Soriano R; Huw L; Stern H; Modrusan Z; Seshagiri S; Hampton GM; Amler LC; Bourgon R; Yauch RL; Shames DS
    Clin Cancer Res; 2012 Apr; 18(8):2360-73. PubMed ID: 22261801
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Validation of SCT Methylation as a Hallmark Biomarker for Lung Cancers.
    Zhang YA; Ma X; Sathe A; Fujimoto J; Wistuba I; Lam S; Yatabe Y; Wang YW; Stastny V; Gao B; Larsen JE; Girard L; Liu X; Song K; Behrens C; Kalhor N; Xie Y; Zhang MQ; Minna JD; Gazdar AF
    J Thorac Oncol; 2016 Mar; 11(3):346-360. PubMed ID: 26725182
    [TBL] [Abstract][Full Text] [Related]  

  • 14. FHIT promoter methylation status, low protein and high mRNA levels in patients with non-small cell lung cancer.
    Czarnecka KH; Migdalska-Sęk M; Domańska D; Pastuszak-Lewandoska D; Dutkowska A; Kordiak J; Nawrot E; Kiszałkiewicz J; Antczak A; Brzeziańska-Lasota E
    Int J Oncol; 2016 Sep; 49(3):1175-84. PubMed ID: 27572663
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Methylation markers of early-stage non-small cell lung cancer.
    Lokk K; Vooder T; Kolde R; Välk K; Võsa U; Roosipuu R; Milani L; Fischer K; Koltsina M; Urgard E; Annilo T; Metspalu A; Tõnisson N
    PLoS One; 2012; 7(6):e39813. PubMed ID: 22768131
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Study of the methylation patterns of the EGFR gene promoter in non-small cell lung cancer.
    Pan ZY; Jiang ZS; Ouyang HQ
    Genet Mol Res; 2015 Aug; 14(3):9813-20. PubMed ID: 26345914
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Molecular heterogeneity of non-small cell lung carcinoma patient-derived xenografts closely reflect their primary tumors.
    Wang D; Pham NA; Tong J; Sakashita S; Allo G; Kim L; Yanagawa N; Raghavan V; Wei Y; To C; Trinh QM; Starmans MH; Chan-Seng-Yue MA; Chadwick D; Li L; Zhu CQ; Liu N; Li M; Lee S; Ignatchenko V; Strumpf D; Taylor P; Moghal N; Liu G; Boutros PC; Kislinger T; Pintilie M; Jurisica I; Shepherd FA; McPherson JD; Muthuswamy L; Moran MF; Tsao MS
    Int J Cancer; 2017 Feb; 140(3):662-673. PubMed ID: 27750381
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Epigenetic predictive biomarkers for response or outcome to platinum-based chemotherapy in non-small cell lung cancer, current state-of-art.
    Szejniuk WM; Robles AI; McCulloch T; Falkmer UGI; Røe OD
    Pharmacogenomics J; 2019 Feb; 19(1):5-14. PubMed ID: 30190521
    [TBL] [Abstract][Full Text] [Related]  

  • 19. PDE3A is hypermethylated in cisplatin resistant non-small cell lung cancer cells and is a modulator of chemotherapy response.
    Tian FM; Zhong CY; Wang XN; Meng Y
    Eur Rev Med Pharmacol Sci; 2017 Jun; 21(11):2635-2641. PubMed ID: 28678321
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Methylation of L1RE1, RARB, and RASSF1 function as possible biomarkers for the differential diagnosis of lung cancer.
    Walter RFH; Rozynek P; Casjens S; Werner R; Mairinger FD; Speel EJM; Zur Hausen A; Meier S; Wohlschlaeger J; Theegarten D; Behrens T; Schmid KW; Brüning T; Johnen G
    PLoS One; 2018; 13(5):e0195716. PubMed ID: 29851970
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 40.